PFAS In Medical Devices: What's New And What To Do

PFAS exposure for device manufacturers no longer hinges on a single rule or a single material. FDA has drawn a firmer line around fluoropolymers, yet state reporting requirements, a still-evolving EU restriction, and shifting supplier availability keep the picture uneven.

An exemption from a product restriction, for example, does not always mean an exemption from disclosure or environmental obligations. This analysis looks at where risk now sits across the product lifecycle, from coatings and processing aids to manufacturing waste, and why documentation and justification matter as much as material choice. It also outlines a practical sequence for prioritizing PFAS uses by function and risk, and for evaluating alternatives as an engineering decision.

Explore the full article to see how readiness takes shape.